Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas

Anticancer Res. 2006 Mar-Apr;26(2B):1351-7.

Abstract

Background: Cerebellar glioblastomas (GBM) are rare tumors whose clinicopathological characteristics are not well understood.

Patients and methods: Clinico-immunohistochemical findings were retrospectively analyzed in 43 supratentorial- and 7 cerebellar GBM. The correlation between survival and immunopositivity for p53, epidermal growth factor receptor (EGFR) and Ki-67 in these tumors was statistically analyzed and compared.

Results: Of the 43 patients with supratentorial GBM, 27 (62.8%) were EGFR immunopositive; their survival was significantly shorter than that of the 16 EGFR-negative patients (p=0.0248). There was no significant correlation between survival and p53 immunopositivity (p=0.7870) and Ki-67 labeling index (p =0.7133). All 5 cerebellar GBM patients treated with radio- and chemotherapy were EGFR-immunonegative; they survived significantly longer than patients with supratentorial GBM (p=0.0296) possibly because their EGFR negativity rendered their tumors more highly radiosensitive.

Conclusion: The better prognosis of patients with cerebellar, EGFR-negative tumors compared to patients with supratentorial tumors is due to the higher radiosensitivity of these tumors.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cerebellar Neoplasms / drug therapy
  • Cerebellar Neoplasms / metabolism*
  • Cerebellar Neoplasms / radiotherapy
  • Cerebellar Neoplasms / surgery
  • Chemotherapy, Adjuvant
  • Child
  • ErbB Receptors / biosynthesis*
  • Female
  • Glioblastoma / drug therapy
  • Glioblastoma / metabolism*
  • Glioblastoma / radiotherapy
  • Glioblastoma / surgery
  • Humans
  • Immunohistochemistry
  • Male
  • Nitrosourea Compounds / administration & dosage
  • Prognosis
  • Radiotherapy, Adjuvant
  • Supratentorial Neoplasms / drug therapy
  • Supratentorial Neoplasms / metabolism*
  • Supratentorial Neoplasms / radiotherapy
  • Supratentorial Neoplasms / surgery
  • Survival Rate
  • Treatment Outcome

Substances

  • Nitrosourea Compounds
  • ErbB Receptors